AUTHORS
Okan Cetin, MD, Andrew Staron, MD2, Natasha J Burke3, Vaishali Sanchorawala, MD4, Raphael E. Szalat, MD, PhD5
AFFILIATIONS
1 Boston Medical Center – Brighton, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
2 Amyloidosis Center, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
3 Amyloidosis Center, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
4 Amyloidosis Center, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States, Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
5 Boston Medical Center, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
ABSTRACT
Background:
Multiple myeloma-associated AL amyloidosis (AL/MM) is a high-risk entity with poorer outcomes than either disease alone. These patients are typically excluded from both AL amyloidosis and MM trials, including the pivotal ANDROMEDA trial, so the impact of frontline daratumumab remains undefined.
Methods:
We retrospectively identified adults evaluated at the Boston University Amyloidosis Center between 2010 and 2026 with concurrent AL/MM, defined as biopsy-proven AL amyloidosis and IMWG-defined MM diagnosed within 6 months of each other. Hematologic and graded cardiac/renal organ responses were assessed by AL amyloidosis consensus criteria; best response was the deepest response achieved before next-line therapy or death, among evaluable patients. Frontline daratumumab-based vs non-daratumumab regimens were compared for hematologic and organ very good partial response or better (≥VGPR), time to next treatment or death (TTNT), and overall survival (OS), both in the overall cohort and within cardiac- and renal-involved subgroups. Multivariable logistic and Cox models were adjusted for cardiac stage and age; a sensitivity analysis added treatment era (frontline therapy started ≥2020 vs <2020). The study was IRB-approved.
Results:
Among 106 patients with concurrent AL/MM who received frontline therapy, median age was 62 years and 58% (61/106) had lambda light-chain disease. Median bone marrow plasma cell infiltration was 38%, and 83% (88/106) had ≥1 vital organ involved (cardiac, renal, hepatic, or nervous system). MM was defined by SLiM criteria alone in 68% (72/106) and by ≥1 CRAB feature in 32% (34/106). Cytogenetic data were available for 70% (74/106), most commonly t(11;14) (35%, 26/74) and 1q gain/amplification (32%, 24/74). Thirty-four percent (36/106) received frontline daratumumab-based therapy. Baseline characteristics were comparable between groups, including age, cardiac/renal involvement, difference between involved and uninvolved free light chains, bone marrow plasma cell percentage, cytogenetics, immunomodulatory drug use, and autologous stem cell transplantation use (17% [6/36] vs 23% [16/70]) (all p>0.05).
Frontline daratumumab was associated with higher hematologic ≥VGPR (among 87 response-evaluable patients: 74% [26/35] vs 46% [24/52]; p=0.01) and longer TTNT (median 55 vs 7 months; p=0.002); OS did not differ significantly (median 74 vs 64 months; p=0.16), though follow-up was shorter in the daratumumab group (median 41 vs 113 months) and the median TTNT may not yet be mature in this group. In multivariable analysis, frontline daratumumab was independently associated with hematologic ≥VGPR (OR 3.78, 95% CI 1.40–10.26; p=0.009) and longer TTNT (HR 0.40, 95% CI 0.23–0.68; p<0.001). In a treatment-era sensitivity analysis, the hematologic ≥VGPR association was attenuated and no longer statistically significant (OR 2.88, 95% CI 0.70–11.91; p=0.14), whereas the association with TTNT remained significant (HR 0.40, 95% CI 0.19–0.85; p=0.018).
Organ-specific analyses showed different patterns. In cardiac-involved patients (n=74; daratumumab n=27, non-daratumumab n=47), daratumumab was associated with deeper hematologic ≥VGPR (81% vs 45%; p=0.007), higher cardiac ≥VGPR (86% vs 32%; p<0.001), longer TTNT (72 vs 6 months; p<0.001), and longer OS (median not reached vs 26 months; p=0.005). In renal-involved patients (n=58; daratumumab n=19, non-daratumumab n=39), daratumumab was associated with deeper hematologic ≥VGPR (84% vs 36%; p=0.001) and longer TTNT (34 vs 6 months; p<0.001), whereas renal ≥VGPR (85% vs 71%; p=0.43) and OS (median 34 vs 39 months; p=0.19) did not differ significantly.
Conclusions:
In this large concurrent AL/MM cohort, frontline daratumumab-based therapy was independently associated with deeper hematologic responses and substantially longer TTNT, with the TTNT benefit persisting after adjustment for treatment era. Particularly favorable outcomes were observed among patients with cardiac involvement. Overall survival did not differ significantly, potentially reflecting shorter follow-up and smaller sample size in the daratumumab group. These real-world data support frontline daratumumab in concurrent AL/MM and underscore the need for prospective study in this understudied population.
DISCLOSURES
Okan Cetin, MD: No relevant conflicts of interest to declare.